Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q3 2023 Earnings Conference Call November 7, 2023 8:00 AM ET

Company Participants

Alexis Callahan - Head of Investor Relations

Sheldon Koenig - President & Chief Executive Officer

Ben Halladay - Chief Financial Officer

JoAnne Foody - Chief Medical Officer

Eric Warren - Chief Commercial Officer

Conference Call Participants

Dennis Ding - Jefferies

Tom Shrader - BTIG

Troy Langford - TD Cowen

Jason Zemansky - Bank of America

Serge Belanger - Needham

Operator

Ladies and gentlemen, thank you for standing by and welcome to Esperion Therapeutics Third Quarter 2023 financial results call. At this time, all participants are in a lisen-only mode. Following the presentation, there will be a question-and-answer session. Please be advised that today's conference may be recorded.

I would now like to hand the conference over to Alexis Callahan, Head of Investor Relations at Esperion. Please go ahead, Alexis.

Alexis Callahan

Thank you, operator. Good morning and welcome to Esperion's Third Quarter 2023 Earnings Conference Call. With us today are Sheldon Koenig, President and CEO; and Ben Halladay, CFO. Other members of the executive team will be available for Q&A. Following our prepared remarks.

I want to remind callers that the information discussed on the call today is covered under the Safe Harbor provisions of the Private Securities Litigation Reform Act. I caution listeners that management will be making forward-looking statements. Actual results could differ materially from those stated or implied by our forward-looking statements due to risks and uncertainties associated with the business. These forward-looking statements are qualified in their entirety by the cautionary statements contained in today's press release and in our SEC filings.

The content of this conference call contains time-sensitive information that is accurate only as of the date of this live broadcast November 7, 2023. We undertake no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this conference call and webcast.

As a reminder, this conference call and webcast are being recorded and archived. We issued a press release earlier this morning detailing the content of today's call. A copy can be found on the Investor page of our website. We will begin the call with prepared remarks and then open the line for your questions.

I'll now turn the call over to Sheldon Koenig, President and Chief Executive Officer.

Sheldon Koenig

Thank you, Alexis, and good morning everyone. Thank you for joining us today to discuss our third quarter results and the progress we continue to make. We are pleased to report another strong quarter. Total revenue was $34 million, which represents a 79% increase year-over-year. US net revenue came in at $20.3 million, which represents a 45% increase year-over-year, and was driven by a 33% year-over-year increase in retail prescription equivalents.